The stock of Patheon NV (NYSE:PTHN) is a huge mover today! About 331,997 shares traded hands. Patheon NV (NYSE:PTHN) has risen 6.00% since October 1, 2016 and is uptrending. It has outperformed by 2.53% the S&P500.
The move comes after 5 months positive chart setup for the $3.59B company. It was reported on Oct, 31 by Barchart.com. We have $42.37 PT which if reached, will make NYSE:PTHN worth $2.41 billion more.
Patheon NV (NYSE:PTHN) Ratings Coverage
Out of 12 analysts covering Patheon (NYSE:PTHN), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Patheon has been the topic of 14 analyst reports since August 15, 2016 according to StockzIntelligence Inc. JP Morgan initiated the stock with “Overweight” rating in Monday, August 15 report. The stock of Patheon NV (NYSE:PTHN) has “Outperform” rating given on Monday, August 15 by Raymond James. William Blair initiated Patheon NV (NYSE:PTHN) on Monday, August 15 with “Outperform” rating. The stock of Patheon NV (NYSE:PTHN) has “Outperform” rating given on Monday, August 15 by Wells Fargo. PiperJaffray initiated it with “Overweight” rating and $32.50 target price in Monday, August 15 report. The rating was initiated by Robert W. Baird with “Outperform” on Monday, August 15. The firm earned “Buy” rating on Tuesday, August 16 by Evercore. The firm has “Outperform” rating given on Tuesday, August 23 by William Blair. Jefferies maintained it with “Buy” rating and $35 target price in Thursday, September 29 report. Piperjaffray initiated the stock with “Overweight” rating in Monday, August 15 report.
According to Zacks Investment Research, “Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands.”
More notable recent Patheon NV (NYSE:PTHN) news were published by: Businesswire.com which released: “Patheon N.V. Announces Pricing of Initial Public Offering” on July 21, 2016, also Businesswire.com with their article: “Patheon N.V. Announces Launch of Initial Public Offering” published on July 11, 2016, Marketwatch.com published: “Patheon started at buy at Evercore ISI” on June 09, 2015. More interesting news about Patheon NV (NYSE:PTHN) were released by: Businesswire.com and their article: “Patheon N.V. Announces Closing of Initial Public Offering and Full Exercise of …” published on July 26, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Patheon NV says three of its manufacturing sites experienced tempora…” with publication date: October 14, 2016.
PTHN Company Profile
Patheon NV, formerly Patheon Holdings Cooperatief U.A., is engaged in providing outsourced pharmaceutical development and manufacturing (CDMO) services. The Firm provides a range of active pharmaceutical ingredient (API) and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and lifecycle management. The Company’s services address both small molecule and large molecule biological drugs. Through the Company’s Patheon OneSource, provide its clients with solutions for both small molecule and large molecule biological pharmaceuticals across its three divisions, including development and manufacturing services for API (Drug Substance Services, or DSS), formulation development and pre-clinical and clinical drug product manufacturing (Pharmaceutical Development Services, or PDS) and commercial drug product manufacturing and packaging (Drug Product Services, or DPS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.